News Sentiment

BNTX sentiment intelligence

BioNTech SE news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 91.48 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-0.0% over one week, +0.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

BioNTech: The Market Is Paying Too Much For An Unproven Pipeline (NASDAQ:BNTX)

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend inactive 0.6% over four weeks
Fair value -9.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 44
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 7
TradingView 6
simplywall.st 5
Seeking Alpha 2
ad-hoc-news.de 2
Ad-hoc-news.de 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 21
Regulatory and legal 4
Guidance 4
Deals and strategy 2
Capital return 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
The Manila Times Direct company coverage

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

BioNTech SE is scheduled to announce its second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will also host a conference call and webcast on the same day at 8:00 a.m. ET to discuss the results and provide a corporate update. Investors and the public can

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 11:10
Source
The Manila Times
Stock Titan Direct company coverage

BioNTech sets Aug. 4 webcast for second-quarter update

BioNTech SE (Nasdaq: BNTX) announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026. On the same day, the company will host a conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss the results and provide a corporate update. I

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 11:10
Source
Stock Titan
Kalkine Media Direct company coverage

BioNTech SE (0A3M) to Announce Q2 2026 Financial Results and Host Investor Call on August 4

BioNTech SE (Nasdaq: BNTX, 0A3M), a biopharmaceutical company, announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026. Concurrently, the company will host a live conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss its qua

Tone
Neutral 50/100
Event
Earnings
Published
21 Jul 2026 11:10
Source
Kalkine Media
European Commission Direct company coverage

German biotech company behind COVID-19 vaccine took its first steps with help from the ERDF

BioNTech, the German biotechnology company behind the Pfizer COVID-19 vaccine, received crucial early support from the European Regional Development Fund (ERDF) in 2009. This funding, totaling EUR 2.2 million, enabled the company to expand its research and development infrastruct

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 19:13
Source
European Commission
ad-hoc-news.de Direct company coverage

The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant

The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) continues to be a key product for Pfizer, with updated formulations targeting current SARS-CoV-2 variants. The article details its development, regulatory approvals for various age groups, manufacturing and distribution challenges

Tone
Positive 71/100
Event
Regulatory and legal
Published
18 Jul 2026 14:58
Source
ad-hoc-news.de
Ad Hoc News Direct company coverage

The BNT162b2 mRNA COVID-19 vaccine. Regulatory milestones shape BioNTech’s core product

BioNTech's BNT162b2 mRNA COVID-19 vaccine has evolved from emergency use to full approval in key markets, serving as both a primary and booster immunization. This product is a crucial driver for BioNTech's stock performance and forms the foundation for its broader mRNA portfolio,

Tone
Positive 70/100
Event
Regulatory and legal
Published
17 Jul 2026 07:10
Source
Ad Hoc News
Market source Direct company coverage

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. Arbutus has also received approximately $178 million from Moderna as part of a

Tone
Negative 33/100
Event
Regulatory and legal
Published
16 Jul 2026 11:41
Source
Market source
Stock Traders Daily Direct company coverage

(BNTX) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of BioNTech SE (NASDAQ: BNTX), highlighting a near-term weak sentiment that may lead to a resumption of long-term weakness. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with spe

Tone
Negative 34/100
Event
Balance sheet
Published
16 Jul 2026 03:41
Source
Stock Traders Daily
Market source Direct company coverage

Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock

Cathie Wood's Ark Invest recently sold over $7.4 million worth of BioNTech stock from its Ark Genomic Revolution ETF, leaving it with a minimal holding. This divestment follows BioNTech's underperformance, projected revenue decline due to reduced COVID-19 vaccine sales, consecuti

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 14:02
Source
Market source
ad-hoc-news.de Direct company coverage

The BNT162b2 vaccine - BioNTech SE bets on mRNA staying power

BioNTech's BNT162b2 mRNA vaccine, co-developed with Pfizer, continues to be a cornerstone of the company's infectious disease portfolio, driving its stock price. The article highlights the vaccine's global reach, complex logistics, and evolving formulations targeting new variants

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 07:11
Source
ad-hoc-news.de
aktiencheck.de Direct company coverage

BioNTech’s Triple Transformation: Shuttering Plants, Losing Founders, and Banking on 15 Cancer Trials

BioNTech is undergoing a significant corporate transformation, closing manufacturing plants and winding down a subsidiary, resulting in approximately 2,000 job cuts. This restructuring is occurring as the company's founders, Ugur Sahin and Özlem Türeci, prepare to depart to pursu

Tone
Negative 40/100
Event
Market update
Published
11 Jul 2026 08:10
Source
aktiencheck.de
Market source Direct company coverage

BioNTech (BNTX) Stock Could Be Overvalued After a 58% Five Year Slump

BioNTech's stock has declined 57.5% over the past five years and is currently screening as overvalued based on market multiples, particularly its Price/Sales ratio of 7.3x compared to a fair implied P/S of 5.3x. Despite ongoing plans to reduce costs by exiting German manufacturin

Tone
Negative 27/100
Event
Market update
Published
10 Jul 2026 05:15
Source
Market source
Investing.com Direct company coverage

Cathie Wood’s ARK sells BioNTech and buys SpaceX stock

Cathie Wood's ARK ETFs engaged in significant trading activity on July 8th, 2026. The firm sold over 78,000 shares of BioNTech and continued its trend of selling Roku and Advanced Micro Devices stock. Conversely, ARK made a substantial purchase of over 181,000 shares of Space Exp

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 00:03
Source
Investing.com
Oncodaily Direct company coverage

Janet Markman: Excited to Become Director of Translational Sciences Oncology at BioNTech

Janet Markman has been promoted to Director of Translational Sciences Oncology at BioNTech SE. She expressed her excitement and gratitude for the support and collaboration of her teams, acknowledging their role in her personal and professional growth. Markman is looking forward t

Tone
Positive 77/100
Event
Market update
Published
08 Jul 2026 14:41
Source
Oncodaily
AD HOC NEWS Direct company coverage

BioNTech SE strengthens its mRNA pipeline as investors watch global demand

BioNTech SE is expanding its mRNA pipeline, focusing on oncology and infectious diseases, beyond its prominent COVID-19 vaccine success. The company aims to convert its scientific platform into sustainable revenue through various cancer vaccine approaches and strategic collaborat

Tone
Positive 69/100
Event
Earnings
Published
07 Jul 2026 22:28
Source
AD HOC NEWS
TradingView Direct company coverage

Enterprise value to EBIT forward of BioNTech SE – NASDAQ:BNTX

This article provides financial data for BioNTech SE (NASDAQ: BNTX), specifically its enterprise value to EBIT forward. It notes that the market for BNTX was closed with no trades. The information is presented by TradingView, sourcing data from ICE Data Services and FactSet Resea

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 11:39
Source
TradingView
Ad-hoc-news.de Direct company coverage

BioNTech stock weighs pipeline and cash runway

BioNTech's stock performance is heavily influenced by its clinical pipeline, partnership model, and the cash reserves accumulated from its COVID-19 vaccine sales. The company's ability to advance late-stage programs while maintaining significant R&D investment is crucial for its

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Jul 2026 20:41
Source
Ad-hoc-news.de
Economies.com Direct company coverage

BioNTech price exposed to negative pressures - Forecast today - 01-07-2026

BioNTech SE (BNTX) experienced a decline in intraday trading due to resistance at its 50-day Simple Moving Average and extremely overbought momentum indicators. The primary short-term bearish trend remains dominant, and the forecast predicts further downside toward the $85.00 sup

Tone
Neutral 50/100
Event
Guidance
Published
01 Jul 2026 12:09
Source
Economies.com
DirectorsTalk Interviews Direct company coverage

BioNTech SE (BNTX) Investor Outlook: Potential Upside of 33.49% Amidst Revenue Challenges

BioNTech SE (BNTX) shows a potential upside of 33.49% with an average target price of $121.77, despite facing challenges such as negative revenue growth (-35.40%) and negative earnings per share. The company's robust pipeline in oncology and infectious diseases, particularly adva

Tone
Positive 60/100
Event
Earnings
Published
29 Jun 2026 10:11
Source
DirectorsTalk Interviews
Oncodaily Direct company coverage

Vikas Sehdev: Starting a New Chapter as Senior Medical Science Liaison at BioNTech SE

Vikas Sehdev has announced his departure from AstraZeneca after five years to join BioNTech SE as a Senior Medical Science Liaison focusing on Breast Cancer. He expressed gratitude for his time at AstraZeneca and enthusiasm for BioNTech's commitment to pioneering innovative thera

Tone
Positive 74/100
Event
Market update
Published
28 Jun 2026 06:39
Source
Oncodaily
TradingView Direct company coverage

Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BSESOF:22UA

This article provides financial data for BioNTech SE Sponsored ADR (BSESOF:22UA) on TradingView, specifically focusing on its enterprise value to forward revenue. It presents a concise overview of the company's financial performance metrics for investors and analysts using the pl

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 19:39
Source
TradingView